These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. Bucci FA; Waterbury LD Curr Med Res Opin; 2011 Dec; 27(12):2235-9. PubMed ID: 21992076 [TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. Walters T; Raizman M; Ernest P; Gayton J; Lehmann R J Cataract Refract Surg; 2007 Sep; 33(9):1539-45. PubMed ID: 17720067 [TBL] [Abstract][Full Text] [Related]
4. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. Bucci FA; Waterbury LD Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702 [TBL] [Abstract][Full Text] [Related]
5. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Heier JS; Awh CC; Busbee BG; Waterbury LD; Daniel P; Stoller GL; Cleary TS Retina; 2009 Oct; 29(9):1310-3. PubMed ID: 19934822 [TBL] [Abstract][Full Text] [Related]
6. Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification. Sahu S; Ram J; Bansal R; Pandav SS; Gupta A J Cataract Refract Surg; 2015 Oct; 41(10):2043-8. PubMed ID: 26703278 [TBL] [Abstract][Full Text] [Related]
7. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels. Bucci FA; Waterbury LD J Cataract Refract Surg; 2008 Sep; 34(9):1509-12. PubMed ID: 18721711 [TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification. Bucci FA; Waterbury LD; Amico LM Am J Ophthalmol; 2007 Jul; 144(1):146-7. PubMed ID: 17601444 [TBL] [Abstract][Full Text] [Related]
9. Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation. Bucolo C; Marrazzo G; Platania CB; Romano GL; Drago F; Salomone S J Pharm Pharmacol; 2014 Jul; 66(7):954-60. PubMed ID: 24697218 [TBL] [Abstract][Full Text] [Related]
10. Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). Durrie DS; Kennard MG; Boghossian AJ Adv Ther; 2007; 24(6):1278-85. PubMed ID: 18165210 [TBL] [Abstract][Full Text] [Related]
12. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery. Jones BM; Neville MW Ann Pharmacother; 2013 Jun; 47(6):892-6. PubMed ID: 23715071 [TBL] [Abstract][Full Text] [Related]
13. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Almeida DR; Khan Z; Xing L; Bakar SN; Rahim K; Urton T; El-Defrawy SR J Cataract Refract Surg; 2012 Sep; 38(9):1537-43. PubMed ID: 22795976 [TBL] [Abstract][Full Text] [Related]